[
  {
    "file_hash": "fd4dbf5c8c232337dfffe8164205a049",
    "drug_name": "213072",
    "application_number": "213072",
    "application_type": "NDA",
    "approval_status": "approved",
    "letter_date": "July 29, 2019",
    "page_count": 7,
    "deficiency_categories": [
      "safety",
      "efficacy",
      "cmc_manufacturing",
      "bioequivalence",
      "labeling",
      "oncology_specific"
    ],
    "has_safety_concerns": true,
    "has_efficacy_concerns": true,
    "requests_new_trial": false,
    "enriched": {
      "formatted_app_number": "NDA213072",
      "openfda_generic_name": null,
      "openfda_brand_name": null,
      "pharm_class": [],
      "adverse_event_count": 0,
      "smiles": null,
      "open_targets_id": null,
      "targets": []
    }
  },
  {
    "file_hash": "17565adb52aa9eda967c642e589d159d",
    "drug_name": "208564",
    "application_number": "208564",
    "application_type": "NDA",
    "approval_status": "approved",
    "letter_date": "July 7, 2016",
    "page_count": 8,
    "deficiency_categories": [
      "safety",
      "efficacy",
      "cmc_manufacturing",
      "bioequivalence",
      "labeling",
      "statistical",
      "oncology_specific"
    ],
    "has_safety_concerns": true,
    "has_efficacy_concerns": true,
    "requests_new_trial": false,
    "enriched": {
      "formatted_app_number": "NDA208564",
      "openfda_generic_name": "ESTRADIOL",
      "openfda_brand_name": "IMVEXXY",
      "pharm_class": [
        "Estrogen [EPC]"
      ],
      "adverse_event_count": 42613,
      "smiles": null,
      "open_targets_id": "CHEMBL135",
      "targets": [
        {
          "symbol": "ESR1",
          "id": "ENSG00000091831",
          "biotype": "protein_coding",
          "genetic_constraint": [
            {
              "constraintType": "syn",
              "score": 0.21560999751091003,
              "oe": 0.9773100018501282,
              "oeLower": 0.8880000114440918,
              "oeUpper": 1.0759999752044678
            },
            {
              "constraintType": "mis",
              "score": 2.460700035095215,
              "oe": 0.7523599863052368,
              "oeLower": 0.7009999752044678,
              "oeUpper": 0.8069999814033508
            },
            {
              "constraintType": "lof",
              "score": 0.99795001745224,
              "oe": 0.29607999324798584,
              "oeLower": 0.19699999690055847,
              "oeUpper": 0.4560000002384186
            }
          ],
          "cancer_hallmarks": [
            {
              "label": "invasion and metastasis",
              "description": "silencing of ESR1 in MCF-7 cell-line induces EMT and expression of specific matrix effectors associated with metastasis"
            },
            {
              "label": "proliferative signalling",
              "description": "activation promotes cell proliferation and resistance to endocrine signals"
            },
            {
              "label": "invasion and metastasis",
              "description": "enhances metastatic capacity"
            },
            {
              "label": "suppression of growth",
              "description": "overexpression of miR-18a decreases ERalpha levels and stimulates cell proliferation"
            },
            {
              "label": "invasion and metastasis",
              "description": "ER alpha in cancer-associated fibroblasts suppresses prostate cancer invasion via modulation of thrombospondin 2 and matrix metalloproteinase 3"
            },
            {
              "label": "escaping immune response to cancer",
              "description": "immune escape mechanisms in ERalpha breast cancer may be facilitated through an ERalpha suppressive mechanism on IFN-gamma signalling"
            }
          ],
          "top_pathways": [
            "Signal Transduction: Estrogen-dependent gene expression",
            "Signal Transduction: Extra-nuclear estrogen signaling",
            "Signal Transduction: PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",
            "Metabolism of proteins: SUMOylation of intracellular receptors",
            "Gene expression (Transcription): Regulation of RUNX2 expression and activity"
          ],
          "oncology_evidence": {
            "disease_name": "breast cancer",
            "overall_association_score": 0.730859921525037,
            "genetic_association_score": 0.7537504412315534,
            "somatic_mutation_score": 0.0
          }
        }
      ]
    }
  },
  {
    "file_hash": "628ee85cea9ef634c70127fd676dac28",
    "drug_name": "Draft Labeling\n6 Page",
    "application_number": "207987",
    "application_type": "NDA",
    "approval_status": "approved",
    "letter_date": "February 12, 2015",
    "page_count": 7,
    "deficiency_categories": [
      "safety",
      "cmc_manufacturing",
      "clinical_trial_design",
      "labeling",
      "statistical",
      "oncology_specific"
    ],
    "has_safety_concerns": true,
    "has_efficacy_concerns": false,
    "requests_new_trial": false,
    "enriched": {
      "formatted_app_number": "NDA207987",
      "openfda_generic_name": "ALCOHOL",
      "openfda_brand_name": "Dehydrated Alcohol",
      "pharm_class": [],
      "adverse_event_count": 24909,
      "smiles": null,
      "open_targets_id": "CHEMBL545",
      "targets": []
    }
  },
  {
    "file_hash": "d610c0725a3693bde6010dd9507b7467",
    "drug_name": null,
    "application_number": "022335",
    "application_type": "NDA",
    "approval_status": "approved",
    "letter_date": "March 26, 2020",
    "page_count": 11,
    "deficiency_categories": [
      "safety",
      "efficacy",
      "cmc_manufacturing",
      "clinical_trial_design",
      "labeling",
      "statistical",
      "oncology_specific"
    ],
    "has_safety_concerns": true,
    "has_efficacy_concerns": true,
    "requests_new_trial": false,
    "enriched": {
      "formatted_app_number": "NDA022335",
      "openfda_generic_name": "KIT FOR THE PREPARATION OF TECHNETIUM TC 99M-LABELED CARBON INHALATION AEROSOL",
      "openfda_brand_name": "TECHNEGAS",
      "pharm_class": [],
      "adverse_event_count": 3,
      "smiles": null,
      "open_targets_id": null,
      "targets": []
    }
  },
  {
    "file_hash": "78cd31a534249df52e6af24e9d179713",
    "drug_name": "209354",
    "application_number": "209354",
    "application_type": "NDA",
    "approval_status": "approved",
    "letter_date": "August 18, 2017",
    "page_count": 6,
    "deficiency_categories": [
      "safety",
      "clinical_trial_design",
      "bioequivalence",
      "labeling",
      "oncology_specific"
    ],
    "has_safety_concerns": true,
    "has_efficacy_concerns": false,
    "requests_new_trial": false,
    "enriched": {
      "formatted_app_number": "NDA209354",
      "openfda_generic_name": "HALOBETASOL PROPIONATE AND TAZAROTENE",
      "openfda_brand_name": "Duobrii",
      "pharm_class": [
        "Retinoid [EPC]"
      ],
      "adverse_event_count": 190,
      "smiles": null,
      "open_targets_id": null,
      "targets": []
    }
  },
  {
    "file_hash": "3cd0d487478ce1b854f6d1420cf1cd54",
    "drug_name": "CRL",
    "application_number": "218828",
    "application_type": "NDA",
    "approval_status": "unapproved",
    "letter_date": null,
    "page_count": 10,
    "deficiency_categories": [
      "safety",
      "efficacy",
      "cmc_manufacturing",
      "clinical_trial_design",
      "bioequivalence",
      "labeling",
      "statistical",
      "oncology_specific"
    ],
    "has_safety_concerns": true,
    "has_efficacy_concerns": true,
    "requests_new_trial": true,
    "enriched": {
      "formatted_app_number": "NDA218828",
      "openfda_generic_name": null,
      "openfda_brand_name": null,
      "pharm_class": [],
      "adverse_event_count": 0,
      "smiles": null,
      "open_targets_id": null,
      "targets": []
    }
  },
  {
    "file_hash": "4af6be116da3c8ebaee9ddeb3df9072f",
    "drug_name": "CRL",
    "application_number": "218524",
    "application_type": "NDA",
    "approval_status": "unapproved",
    "letter_date": null,
    "page_count": 7,
    "deficiency_categories": [
      "safety",
      "labeling",
      "oncology_specific"
    ],
    "has_safety_concerns": true,
    "has_efficacy_concerns": false,
    "requests_new_trial": false,
    "enriched": {
      "formatted_app_number": "NDA218524",
      "openfda_generic_name": null,
      "openfda_brand_name": null,
      "pharm_class": [],
      "adverse_event_count": 0,
      "smiles": null,
      "open_targets_id": null,
      "targets": []
    }
  },
  {
    "file_hash": "c141a8867dbf6bd1b04be3cd2afc459d",
    "drug_name": "CRL",
    "application_number": null,
    "application_type": null,
    "approval_status": "unapproved",
    "letter_date": "July 7, 2025",
    "page_count": 18,
    "deficiency_categories": [
      "safety",
      "efficacy",
      "cmc_manufacturing",
      "clinical_trial_design",
      "labeling",
      "oncology_specific"
    ],
    "has_safety_concerns": true,
    "has_efficacy_concerns": true,
    "requests_new_trial": false,
    "enriched": {
      "formatted_app_number": "",
      "openfda_generic_name": null,
      "openfda_brand_name": null,
      "pharm_class": [],
      "adverse_event_count": 0,
      "smiles": null,
      "open_targets_id": null,
      "targets": []
    }
  },
  {
    "file_hash": "5496ab91b576b83d02fd8d4c36d1d9ad",
    "drug_name": "CRL",
    "application_number": "218762",
    "application_type": "NDA",
    "approval_status": "unapproved",
    "letter_date": null,
    "page_count": 5,
    "deficiency_categories": [
      "safety",
      "labeling",
      "oncology_specific"
    ],
    "has_safety_concerns": true,
    "has_efficacy_concerns": false,
    "requests_new_trial": false,
    "enriched": {
      "formatted_app_number": "NDA218762",
      "openfda_generic_name": null,
      "openfda_brand_name": null,
      "pharm_class": [],
      "adverse_event_count": 0,
      "smiles": null,
      "open_targets_id": null,
      "targets": []
    }
  },
  {
    "file_hash": "a9b2a2785ddcc4872b40b859176526ba",
    "drug_name": "CRL",
    "application_number": "215818",
    "application_type": "NDA",
    "approval_status": "unapproved",
    "letter_date": null,
    "page_count": 9,
    "deficiency_categories": [
      "safety",
      "labeling",
      "oncology_specific"
    ],
    "has_safety_concerns": true,
    "has_efficacy_concerns": false,
    "requests_new_trial": false,
    "enriched": {
      "formatted_app_number": "NDA215818",
      "openfda_generic_name": null,
      "openfda_brand_name": null,
      "pharm_class": [],
      "adverse_event_count": 0,
      "smiles": null,
      "open_targets_id": null,
      "targets": []
    }
  }
]